Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 1;59(8):1853-1861.
doi: 10.1093/rheumatology/kez497.

Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'

James M Gwinnutt  1 , Kimme L Hyrich  1   2 , Mark Lunt  1 ; RAMS Co-Investigators; Anne Barton  2   3 , Suzanne M M Verstappen  1   2
Affiliations

Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'

James M Gwinnutt et al. Rheumatology (Oxford). .

Abstract

Objectives: To describe outcomes of patients with early RA in a patient acceptable symptom state (PASS) at treatment initiation and to identify clusters of symptoms associated with poor outcomes.

Methods: Data came from the Rheumatoid Arthritis Medication Study, a UK multicentre cohort study of RA patients starting MTX. The HAQ, DAS28 and other patient-reported outcome measures (PROMs) were collected at baseline, and at 6 and 12 months. Patients answering yes to the question 'Is your current condition satisfactory, when you take your general functioning and your current pain into consideration?' were defined as PASS; patients answering no were defined as N-PASS. Symptom clusters in the baseline PASS group were identified using K-medians cluster analysis. Outcomes of baseline PASS vs N-PASS patients and each cluster are compared using random effects models.

Results: Of 1127 patients, 572 (50.8%) reported being in PASS at baseline. Over one year, baseline PASS patients had lower DAS28 (mean difference = -0.71, 95% CI -0.83, -0.59) and HAQ scores (mean difference = -0.48, 95% CI -0.56, -0.41) compared with N-PASS patients. Within the baseline PASS group, we identified six symptom clusters. Clusters characterized by high disease activity and high PROMs, or moderate disease activity and high PROMs, had the worst outcomes compared with the other clusters.

Conclusion: Despite reporting their condition as 'satisfactory', early RA patients with high PROM scores are less likely to respond to therapy. This group may require increased vigilance to optimize outcomes.

Keywords: cluster analysis; disability; epidemiology; patient acceptable symptom state; rheumatoid arthritis.

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Outcomes over 12 months of follow-up, stratified by cluster (A) HAQ, (B) DAS28, (C) pain-VAS, (D) fatigue-VAS and (E) HADS-depression. *Moderate level PROMs other than HADS-depression, which was high. H: high; HADS: Hospital Anxiety and Depression Scale; L: low; M: moderate; PROMs: patient-reported outcome measures; VAS: visual analogue scale.
See this image and copyright information in PMC

References

    1. Smolen JS, Landewé R, Breedveld FC. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509. - PMC - PubMed
    1. Smolen JS, Breedveld FC, Burmester GR. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3–15. - PMC - PubMed
    1. Hetland ML, Christensen IJ, Tarp U. et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22–32. - PubMed
    1. Verstappen SM, Jacobs JW, van der Veen MJ. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443–9. - PMC - PubMed
    1. Heiberg T, Kvien TK, Mowinckel P, Aletaha D. et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:967–71. - PubMed

Publication types

Substances